Reply to "Letter to Dobesh et al. on lower mortality with andexanet alfa in factor Xa inhibitor-related major bleeding".
作者信息
Dobesh Paul P, Fermann Gregory J, Christoph Mary J, Koch Bruce, Lesén Eva, Chen Hungta, Lovelace Belinda, Dettling Theresa, Danese Mark, Ulloa Julie, Danese Sherry, Coleman Craig I
机构信息
Department of Pharmacy Practice and Science, University of Nebraska Medical Center, College of Pharmacy, Omaha, Nebraska, USA.
Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
出版信息
Res Pract Thromb Haemost. 2024 Apr 27;8(4):102429. doi: 10.1016/j.rpth.2024.102429. eCollection 2024 May.
Abstract
摘要
相似文献
1
Reply to "Letter to Dobesh et al. on lower mortality with andexanet alfa in factor Xa inhibitor-related major bleeding".
Res Pract Thromb Haemost. 2024 Apr 27;8(4):102429. doi: 10.1016/j.rpth.2024.102429. eCollection 2024 May.
2
Letter to Dobesh et al. on lower mortality with andexanet alfa in factor Xa inhibitor-related major bleeding.
Res Pract Thromb Haemost. 2024 Apr 27;8(4):102428. doi: 10.1016/j.rpth.2024.102428. eCollection 2024 May.
3
Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate.
J Thromb Thrombolysis. 2023 Jul;56(1):137-146. doi: 10.1007/s11239-023-02820-y. Epub 2023 May 23.
4
Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis.
Crit Care Med. 2021 Oct 1;49(10):e1025-e1036. doi: 10.1097/CCM.0000000000005059.
5
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
Circulation. 2023 Mar 28;147(13):1026-1038. doi: 10.1161/CIRCULATIONAHA.121.057844. Epub 2023 Feb 20.
6
Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa.
J Thromb Haemost. 2020 Oct;18(10):2532-2541. doi: 10.1111/jth.15031. Epub 2020 Aug 27.
7
Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.
Res Pract Thromb Haemost. 2023 Aug 30;7(6):102192. doi: 10.1016/j.rpth.2023.102192. eCollection 2023 Aug.
8
Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series.
Am J Health Syst Pharm. 2022 Aug 5;79(16):1323-1329. doi: 10.1093/ajhp/zxac079.
9
An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage.
Clin Neurol Neurosurg. 2020 Aug;195:106070. doi: 10.1016/j.clineuro.2020.106070. Epub 2020 Jul 4.
10
Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding.
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211039020. doi: 10.1177/10760296211039020.
本文引用的文献
1
Letter to Dobesh et al. on lower mortality with andexanet alfa in factor Xa inhibitor-related major bleeding.
Res Pract Thromb Haemost. 2024 Apr 27;8(4):102428. doi: 10.1016/j.rpth.2024.102428. eCollection 2024 May.
2
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.
N Engl J Med. 2024 May 16;390(19):1745-1755. doi: 10.1056/NEJMoa2313040.
3
Prothrombin Complex Concentrate vs Conservative Management in ICH Associated With Direct Oral Anticoagulants.
JAMA Netw Open. 2024 Feb 5;7(2):e2354916. doi: 10.1001/jamanetworkopen.2023.54916.
4
Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.
Res Pract Thromb Haemost. 2023 Aug 30;7(6):102192. doi: 10.1016/j.rpth.2023.102192. eCollection 2023 Aug.
5
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
Crit Care. 2022 Jun 16;26(1):180. doi: 10.1186/s13054-022-04043-8.
Zotero 插件